Compare QDEL & MESO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | QDEL | MESO |
|---|---|---|
| Founded | 1979 | 2004 |
| Country | United States | Australia |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.8B |
| IPO Year | N/A | N/A |
| Metric | QDEL | MESO |
|---|---|---|
| Price | $29.83 | $18.50 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 6 | 2 |
| Target Price | ★ $39.33 | $24.00 |
| AVG Volume (30 Days) | ★ 1.2M | 195.5K |
| Earning Date | 11-05-2025 | 08-28-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $2,714,400,000.00 | $17,198,000.00 |
| Revenue This Year | N/A | $465.44 |
| Revenue Next Year | $2.42 | $75.37 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 191.39 |
| 52 Week Low | $19.50 | $9.61 |
| 52 Week High | $49.45 | $22.00 |
| Indicator | QDEL | MESO |
|---|---|---|
| Relative Strength Index (RSI) | 65.19 | 63.70 |
| Support Level | $26.84 | $16.43 |
| Resistance Level | $28.30 | $17.65 |
| Average True Range (ATR) | 1.31 | 0.63 |
| MACD | 0.50 | 0.32 |
| Stochastic Oscillator | 93.41 | 82.57 |
QuidelOrtho Corp is engaged in the development, manufacturing and marketing of rapid diagnostic testing solutions. The company is engaged in immunoassay and molecular testing, clinical chemistry and transfusion medicine which helps clinicians and patients to make decisions across the globe. Geographically the company has its presence in North America, EMEA, China and Other countries. It generates majority if its revenue from North America.
Mesoblast Ltd is a commercial-stage biotechnology company and a world leader in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The company's product candidates include: Ryoncil (remestemcel-L) for the treatment of steroid-refractory acute graft versus host disease, as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of an adult stem cell technology platform for commercialization.